Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Dean Li

Chris Gibson

Blake Borgeson

Recursion Pharmaceuticals, Inc.

Primordial AI utilizes evolutionary data and artificial intelligence to discover drug targets, focusing on achieving next-generation drug development.

Primordial AI

Novus Software specializes in developing software products tailored for the pharmaceutical industry, focusing on cloud technology, automation, and artificial intelligence (AI) to enhance operations and ensure compliance.

Metric
Company Name	Recursion Pharmaceuticals, Inc.	Primordial AI	Novus Software
Symbol	RXRX
MSH ID	COM:RECURSION	COM:PRIMORDIALBIO	IN:NOVUSSOFTWARE
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Technology
Industry	Biotechnology	Biotechnology	Pharmaceutical Software
Country	US	US	IN
Stage		Seed
Employee Count	500
Website	recursion.com	primordialbio.com	novussoftware.in
LinkedIn		primordial-ai	novussoftware
Founders

Metric
Market Cap	1.89B
Enterprise Value
Monthly Web Traffic		1.24K
Web Traffic Growth		-0.54
Valuation
Raised Capital		4M

Metric
Revenue	44.58M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-6.51M
EBITDA	-317.60M
Operating Income	-350.06M
Net Income	-328.07M
EPS	-1.58
Diluted EPS	-1.58
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.18
Operating Profit Margin	-8.16
EBITDA Margin	-7.12
Net Profit Margin	-7.33
Return on Equity	-0.72
Return on Assets	-0.48
Return on Capital Employed	-0.59

COM:RECURSION

Recursion

Last Close

5.75

22/11 21:00

Market Cap

1.89B

Beta: -

Volume Today

60.41K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-6.78
P/B Ratio	4.46
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	50.53
EV Multiple	-5.47

Metric
Days Sales Outstanding	24.61
Days Payables Outstanding	35.75
Days Inventory Outstanding
Operating Cycle	25.58
Cash Conversion Cycle	-0.10
Asset Turnover	0.08

Metric
Operating Cash Flow	-287.78M
Free Cash Flow	-300.33M
Cash Flow to Debt	-7.99
Operating Cash Flow/Sales	-6.44
Free Cash Flow Yield	-0.14

Metric
Cash & Equivalents	394.80M
Accounts Receivable	-7.76M
Inventory	-3.09M
Goodwill	52.06M
Debt to Capitalization	0.06
Debt to Assets	0.08
Current Ratio	4.36
Quick Ratio	6.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.96
R&D to Revenue	4.60
SG&A to Revenue	2.14